Home » FDA » Page 11

Tag Archives: FDA

Moving Towards Greater Transparency – One Step At A Time, Inexorably

Posted on by — No Comments ↓

Sharing trial data has been a controversial topic for quite a while. Recently the editors of major medical journals decided to take a stand. They will make access to trial source data a requirement, as a condition of publication, arguing that patients and the scientific community have a right to this Continue reading Moving Towards Greater Transparency – One Step At A Time, Inexorably→

New Treatment Guidelines for Candidiasis – A Major Document to Study

Posted on by — No Comments ↓

In a much-quoted analysis, Lee found that most IDSA Guidelines were supported only by Level III quality data, the lowest category of evidence-based support[1]. The article concludes that more well-designed trials were needed, and clinical judgement should ultimately guide patient management. This all sounds fine and good, and the new Continue reading New Treatment Guidelines for Candidiasis – A Major Document to Study→

Eravacycline Conference Call: Unrevealing and Disappointing

Posted on by — No Comments ↓

Whatever has become of investigative journalism?  All we read after the Stifel conference call (11/17/2015) is descriptive rehash of information provided by Tetraphase at the conference.  No probing questions that we thought investors would ask who just lost 80% of their money.  No signs of analytical or strategic readjustment at Continue reading Eravacycline Conference Call: Unrevealing and Disappointing→